Related Experiment Video
Updated: Apr 20, 2026
Establishment of a Clinic-based Biorepository
Published on: May 29, 2017
Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell
Torsten Holm Nielsen1, Zuanel Diaz2, Rosa Christodoulopoulos3
1Lady Davis Institute for Medical Research, McGill University, Quebec, Canada.
Abstract:
Increasingly, targeted therapies are being developed to treat malignancies. To define targets, determine mechanisms of response and resistance, and develop biomarkers for the successful investigation of novel therapeutics, high-quality tumor biospecimens are critical. We have developed standard operating procedures (SOPs) to acquire and process serial blood and tumor biopsies from patients with diffuse large B-cell lymphoma enrolled in multicenter clinical trials. These SOPs allow for collection and processing of materials suitable for multiple downstream applications, including immunohistochemistry, cDNA microarrays, exome sequencing, and metabolomics. By standardizing these methods, we control preanalytic variables that ensure high reproducibility of results and facilitate the integration of datasets from such trials. This will facilitate translational research, better treatment selection, and more rapid and efficient development of new drugs. See all the articles in this CEBP Focus section, "Biomarkers, Biospecimens, and New Technologies in Molecular Epidemiology."
Insights
Standardized biospecimen collection and processing methods are crucial for developing targeted cancer therapies. These SOPs ensure high-quality samples for biomarker discovery and drug development in diffuse large B-cell lymphoma clinical trials.
Area of Science:
- Oncology
- Translational Research
- Molecular Epidemiology
Background:
- Targeted therapies are advancing cancer treatment.
- High-quality biospecimens are essential for identifying therapeutic targets, understanding drug response/resistance, and developing biomarkers.
- Diffuse large B-cell lymphoma (DLBCL) research requires robust sample handling.
Purpose of the Study:
- To establish standardized operating procedures (SOPs) for acquiring and processing serial blood and tumor biopsies.
- To ensure biospecimen quality for diverse downstream molecular analyses.
- To facilitate translational research and accelerate the development of novel therapeutics for DLBCL.
Main Methods:
- Development and implementation of SOPs for serial blood and tumor biopsy collection.
- Processing of biospecimens for various applications: immunohistochemistry, cDNA microarrays, exome sequencing, and metabolomics.
- Standardization of preanalytic variables across multicenter clinical trials.
Main Results:
- Established reproducible methods for collecting and processing high-quality biospecimens.
- Enabled downstream analyses including molecular profiling and biomarker discovery.
- Controlled preanalytic variables to ensure data integrity and facilitate dataset integration.
Conclusions:
- Standardized biospecimen handling is critical for reproducible results in translational research.
- These SOPs support the development of biomarkers and accelerate novel drug development in DLBCL.
- Facilitates better treatment selection and more efficient clinical trial outcomes.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018